Recombinant Canine CTLA-4 Fc Chimera, CF

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

CTLA-4 (cytotoxic T-lymphocyte-4, designated CD152), is a type I transmembrane T cell inhibitory molecule that is a member of the Ig superfamily (1, 2). Canine CTLA-4 cDNA A encodes 223 amino acids (aa) including a 35 aa signal sequence, a 126 aa extracellular domain (ECD) with one Ig-like V-type domain, a 21 aa transmembrane (TM) sequence, and a 41 aa cytoplasmic sequence.Within the ECD, canine CTLA-4 shares 84%, 69%, and 71% aa sequence identity with human, mouse and rat CTLA-4 respectively. CD28, which is structurally related to CTLA-4, is constitutively expressed on naïve T cells and promotes T cell activation when engaged by B7-2 on antigen-presenting cells (APC) within the immunological synapse (IS) (1, 3, 4). In contrast, CTLA-4 is recruited from intracellular vesicles to the IS beginning 1, 2 days after T cell activation (2, 3, 4). It forms a linear lattice with B7‑1 on APC, inducing negative regulatory signals and ending T cell activation (5). Abatacept, a therapeutic human CTLA-4-Ig fusion protein (trade name Orencia), competes with CD28 for B7-1 and B7-2 binding and has been used to antagonize T cell activation in autoimmune conditions and to enhance transplant survival (6). Mice deleted for CTLA-4 show no abnormalities until after birth, but then develop lethal autoimmune reactions due to continued T cell activation and poor control by regulatory T cells, which constitutively express CTLA-4 in wild-type mice and humans (7‑9).

Array 10954-CT

• CTLA-4 Antibodies
• CTLA-4 Antibody Pair
• CTLA-4 ELISA Kits
• CTLA-4 Lysate
• CTLA-4 Protein
• CTLA-4 Proteins and Enzymes
• CTLA-4 ELISAs